Donghwa Kim

Seoul National University — South Korea

Medicine · Health Sciences

23h-index1.8kcitations118works4.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(24), PI3K/AKT/mTOR signaling in cancer(15), HER2/EGFR in Cancer Research(14), Cancer Genomics and Diagnostics(12), Colorectal Cancer Treatments and Studies(11)

Publications118 total

Acquired resistance in cancer: towards targeted therapeutic strategies
Nature reviews. Cancer·2025· 37 citedOpen Access
Actionable biological programs to enhance EGFR-targeted therapy response unveiled by single-cell lineage tracing in clinically relevant lung cancer models
2025Open Access
Author response: Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer
2025Open Access
Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer
eLife·2025· 5 citedOpen Access
Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer
2025Open Access
Author response: Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer
2025Open Access
Abstract 4653: Unraveling the vulnerabilities of targeted therapy-tolerant persister cells in NSCLC
Cancer Research·2024
Reviewer #1 (Public Review): Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer
2024Open Access
Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer
2024Open Access
Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer
eLife·2024· 4 citedOpen Access
Reviewer #2 (Public Review): Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer
2024Open Access
Antiproliferative Activity of Gibbosic Acid H through Induction of G<sub>0</sub>/G<sub>1</sub> Cell Cycle Arrest and Apoptosis in Human Lung Cancer Cells
Journal of Cancer Prevention·2023· 3 citedOpen Access
Combinatorial CRISPR screen reveals <i>FYN</i> and <i>KDM4</i> as targets for synergistic drug combination for treating triple negative breast cancer
2023· 1 citedOpen Access
Supplementary Tables 2 - 5, Figures 2 - 3 from A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer
2023Open Access
Data from A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer
2023Open Access
Supplementary Table 1 from A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer
2023Open Access
Supplementary Tables 2 - 5, Figures 2 - 3 from A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer
2023Open Access
Supplementary Figure 1 from A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer
2023Open Access
Supplemental Figure 2 from IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non–Small Cell Lung Cancer with Activating Mutations of EGFR
2023Open Access
Data from IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non–Small Cell Lung Cancer with Activating Mutations of EGFR
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Sang Kook Lee(30), Hyen Joo Park(9), Duc‐Hiep Bach(8), Yanhua Fan(8), Ji‐Young Hong(8), Jin Q. Cheng(8), Thi-Thu-Trang Luu(7), Yongnan Xu(5), Jongheon Shin(5), Dong‐Chan Oh(5), Satoshi Kaneko(4), Cai Yi Wang(4), Ruoci Hu(4), Hee-Juhn Park(4), Richard Jove(3), Won Kyung Kim(3), Jianyu Liu(3), Woong Sub Byun(3), Heng‐Shan Wang(3), Ki‐Bong Oh(3)